# MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

> **NCT00430352** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 545 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** rituximab [MabThera/Rituxan]

## Key facts

- **NCT ID:** NCT00430352
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-04
- **Primary completion:** 2011-05-26
- **Final completion:** 2011-05-26
- **Target enrollment:** 545 (ACTUAL)
- **Last updated:** 2017-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00430352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00430352, "MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00430352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*